Executives From Leading Pharmaceutical and Biotech Companies Discuss Industry Trends at Annual Bourne Partners Summit
September 8, 2015
EXECUTIVES FROM LEADING PHARMACEUTICAL AND BIOTECH COMPANIES DISCUSS INDUSTRY TRENDS AT ANNUAL BOURNE PARTNERS GLOBAL HEALTHCARE SUMMIT
Eshelman Ventures LLC Founder and Former PPD CEO Fred Eshelman shared thoughts on business development, investment philosophy and recent appointment
CHARLOTTE, N.C. (Sept. 8, 2015) – The fifth annual Bourne Partners Global Healthcare Executive Summit was recently held in Charlotte, N.C., and featured top executives from leading pharmaceutical, pharma services, specialty pharma, biotech companies and investors discussing a variety of trends and topics including pharmaceutical entrepreneurialism; healthcare services; consumer healthcare and branding; and global biotech.
The two-day event was hosted by Bourne Partners, a leading healthcare and consumer healthcare investment banking, merchant banking, and investment firm, comprised of Bourne Capital Partners, LLC (BCP) and Bourne Partners Alternative Assets (BPAA).
“Our annual conference enables us to gather some of the brightest minds in the healthcare industry to share knowledge and be an essential and informative resource for our partners, clients, and investors,” said Banks Bourne, who founded Bourne Partners in 2001 and currently serves as its CEO and Senior Managing Director. “Our goal is to create a unique and productive event that fosters long-term, profitable relationships for all involved.”
Speakers included Eshelman Ventures LLC founder and former Pharmaceutical Product Development, LLC (PPD) CEO Dr. Fred Eshelman; Covis Pharma Sàrl CEO Jack Davis; National Surgical Healthcare Chairman and CEO David Crane; Merz North America President and CEO Bill Humphries; Princeton Biopharma LLC Chairman and CEO Michael Wells; SeLux Diagnostics, Inc. Chairman and CEO David W. Bryant; Agilem Strategy LLC CEO and Founder Michael Kane; Exeltis USA CEO Maria Carell; Beacon Consulting Group President Kevin Rooney; and Senior OTC Commercial Executive Bruce Montgomery.
Eshelman spoke to the crowd about building PPD into a multibillion-dollar company, his investment philosophy and recent appointment as non-executive Chairman of The Medicines Company Board of Directors.
“When we started building PPD I never would have believed if someone had told me we would one day sell it for $3.9 billion,” said Eshelman. “It was constantly a learning experience for me and I really enjoyed growing the business as an entrepreneur. The Medicines Group is another exciting opportunity with a company that has great potential and a very opportunistic pipeline.”
Conference attendees included global healthcare and consumer executives from a variety of disciplines, including the pharmaceutical, hospital and healthcare technology sectors; private equity investors; and partners, investors, and clients of Bourne Partners. As part of the program, participants were treated to a special guest speaker, four-time NASCAR Series Champion Jeff Gordon, who discussed teamwork, risk-taking and the business of motorsports.
To learn more, visit Bourne-Partners.com.